Zobrazeno 1 - 8
of 8
pro vyhledávání: '"John R. Sanchez"'
Autor:
Kristin A. Altwegg, Uday P. Pratap, Zexuan Liu, Junhao Liu, John R. Sanchez, Xue Yang, Behnam Ebrahimi, Durga Meenakshi Panneerdoss, Xiaonan Li, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Manjeet K. Rao, Ratna K. Vadlamudi
Publikováno v:
Breast Cancer Research and Treatment. 200:151-162
Purpose Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Oncogenic PELP1 is frequently overexpressed in TNBC, and it has been demonstrated that PELP1 signaling is essential for TNBC progression. The therapeutic ut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::471de0f99b69c5d30e715ee10ca18fff
https://doi.org/10.1007/s10549-023-06958-4
https://doi.org/10.1007/s10549-023-06958-4
Autor:
Ratna K. Vadlamudi, Hariprasad Vankayalapati, Manjeet K. Rao, Tim H.-M. Huang, Stan McHardy, Rajeshwar R. Tekmal, Gangadhara R. Sareddy, Daohong Zhou, Yaxia Yuan, Ganesh V. Raj, Zhao Lai, Yidong Chen, Bindu Santhamma, Ben H. Park, Shihong Ma, Xiaonan Li, John R. Sanchez, Behnam Ebrahimi, Uday P. Pratap, Junhao Liu, Zexuan Liu, Samaya Krishnan, Dimple Chakravarty, Monica Mann, Suryavathi Viswanadhapalli, Kristin A. Altwegg
Supplementary Table from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dec87bf5129a56562dd1e9b0f35ea60d
https://doi.org/10.1158/0008-5472.22432374
https://doi.org/10.1158/0008-5472.22432374
Supplementary Data from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer
Autor:
Ratna K. Vadlamudi, Hariprasad Vankayalapati, Manjeet K. Rao, Tim H.-M. Huang, Stan McHardy, Rajeshwar R. Tekmal, Gangadhara R. Sareddy, Daohong Zhou, Yaxia Yuan, Ganesh V. Raj, Zhao Lai, Yidong Chen, Bindu Santhamma, Ben H. Park, Shihong Ma, Xiaonan Li, John R. Sanchez, Behnam Ebrahimi, Uday P. Pratap, Junhao Liu, Zexuan Liu, Samaya Krishnan, Dimple Chakravarty, Monica Mann, Suryavathi Viswanadhapalli, Kristin A. Altwegg
Supplementary Data from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::959d7bbb0ef81c60f20cfbe0f25bc169
https://doi.org/10.1158/0008-5472.22432383
https://doi.org/10.1158/0008-5472.22432383
Autor:
Ratna K. Vadlamudi, Hariprasad Vankayalapati, Manjeet K. Rao, Tim H.-M. Huang, Stan McHardy, Rajeshwar R. Tekmal, Gangadhara R. Sareddy, Daohong Zhou, Yaxia Yuan, Ganesh V. Raj, Zhao Lai, Yidong Chen, Bindu Santhamma, Ben H. Park, Shihong Ma, Xiaonan Li, John R. Sanchez, Behnam Ebrahimi, Uday P. Pratap, Junhao Liu, Zexuan Liu, Samaya Krishnan, Dimple Chakravarty, Monica Mann, Suryavathi Viswanadhapalli, Kristin A. Altwegg
Supplementary Figure from A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d89245a913219976866a2fc67bad0a4
https://doi.org/10.1158/0008-5472.22432380
https://doi.org/10.1158/0008-5472.22432380
Autor:
Ratna K. Vadlamudi, Hariprasad Vankayalapati, Manjeet K. Rao, Tim H.-M. Huang, Stan McHardy, Rajeshwar R. Tekmal, Gangadhara R. Sareddy, Daohong Zhou, Yaxia Yuan, Ganesh V. Raj, Zhao Lai, Yidong Chen, Bindu Santhamma, Ben H. Park, Shihong Ma, Xiaonan Li, John R. Sanchez, Behnam Ebrahimi, Uday P. Pratap, Junhao Liu, Zexuan Liu, Samaya Krishnan, Dimple Chakravarty, Monica Mann, Suryavathi Viswanadhapalli, Kristin A. Altwegg
Most patients with estrogen receptor alpha–positive (ER+) breast cancers initially respond to treatment but eventually develop therapy resistance with disease progression. Overexpression of oncogenic ER coregulators, including proline, glutamic aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::271b1f1ca67ad13d7206cb0b1bf53446
https://doi.org/10.1158/0008-5472.c.6514131.v1
https://doi.org/10.1158/0008-5472.c.6514131.v1
Autor:
Kristin A. Altwegg, Suryavathi Viswanadhapalli, Monica Mann, Dimple Chakravarty, Samaya Krishnan, Zexuan Liu, Junhao Liu, Uday P. Pratap, Behnam Ebrahimi, John R. Sanchez, Xiaonan Li, Shihong Ma, Ben H. Park, Bindu Santhamma, Yidong Chen, Zhao Lai, Ganesh V. Raj, Yaxia Yuan, Daohong Zhou, Gangadhara R. Sareddy, Rajeshwar R. Tekmal, Stan McHardy, Tim H.-M. Huang, Manjeet K. Rao, Hariprasad Vankayalapati, Ratna K. Vadlamudi
Publikováno v:
Cancer Res
Most patients with estrogen receptor alpha–positive (ER+) breast cancers initially respond to treatment but eventually develop therapy resistance with disease progression. Overexpression of oncogenic ER coregulators, including proline, glutamic aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::944e72002e917512ff4b8bc0a49a70a3
https://europepmc.org/articles/PMC9588738/
https://europepmc.org/articles/PMC9588738/
Publikováno v:
BMJ case reports. 15(9)
We report here a woman in her 70s presenting with adrenal insufficiency secondary to a primary adrenal lymphoma. The patient had a previous history of aphthous ulcers on dexamethasone and was referred to endocrinology with symptoms of fatigue and ort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a28aff12aeba7ed6a58c3dc314271592
https://pubmed.ncbi.nlm.nih.gov/36167431
https://pubmed.ncbi.nlm.nih.gov/36167431
Autor:
Kristin Ann Altwegg, Monica Mann, Dimple Chakravarty, Zexuan Liu, Junhao Liu, Uday P. Pratap, Behnam Ebrahimi, John R. Sanchez, Ben H. Park, Hariprasad Vankayalapati, Gangadhara R. Sareddy, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi
Publikováno v:
Cancer Research. 82:648-648
A significant proportion of estrogen receptor positive breast cancers (ER+BC) will initially respond to treatment, but many eventually develop therapy resistance (TR-BC), and progress to incurable metastases. Oncogenic ER coregulators overexpressed i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d633b50bd0ea279a61330eabc4ea0cc9
https://doi.org/10.1158/1538-7445.am2022-648
https://doi.org/10.1158/1538-7445.am2022-648